Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy±everolimusin patients with high-risk, hormone receptor (HR) positive, HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)

Autor:	Julie R. Gralow, W. Barlow, Eleftherios P. Mamounas, Lajos Pusztai, Gabriel N. Hortobagyi, J. Miao, Patricia A. Ganz, Mariana Chavez-MacGregor, H. Bandos, P. Rastogi
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty business.industry medicine.medical_treatment HER2 negative Endocrine therapy General Medicine Placebo medicine.disease Clinical trial Breast cancer Hormone receptor Internal medicine Medicine Surgery business Adjuvant
Zdroj:	The Breast. 44:S139
ISSN:	0960-9776
DOI:	10.1016/s0960-9776(19)30460-6
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::528040b632c8b2ca1eb55acad1585889 https://doi.org/10.1016/s0960-9776(19)30460-6 Zobrazit plný text záznamu Full Text from ScienceDirect